Zealand Pharma A/S, A Biotechnology Company Focused On The Discovery, Development And Commercialization Of Innovative Peptide-Based Medicines, Announced Completion Of Patient Enrollment In The Second Phase 3-Trial, 17103, Of Dasiglucagon For The Treatment Of Congenital Hyperinsulinism (Chi) In Neonates Up To 12 Months Old. This Phase 3 Study Is The Last In The Program Which Constitute The Largest Clinical Development Programme Ever Conducted In Chi.Chi Is The Most Frequent Cause Of Severe And Persistent Hypoglycemia. It Starts As Early As The Neonatal Period And Profoundly Affects Those Children And Their Families Through Infancy And Teenage Years. It Is Characterized By An Excessive And Uncontrolled Insulin Secretion Triggering Recurrent Episodes Of Profound Hypoglycemia Which Require Constant Surveillance And Rapid And Intensive Interventions To Prevent Neurological Sequelae.
